Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.
BACKGROUND
Sirolimus-eluting coronary stents (SESs) and paclitaxel-eluting coronary stents (PESs) are used to reduce restenosis but have different sites of action. The molecular targets of sirolimus overlap with those of the peroxisome proliferator-activated receptor (PPAR)gamma agonist rosiglitazone (RSG) but the consequence of this interaction on endothelialization is unknown.


OBJECTIVE
Using the New Zealand white rabbit iliac model of stenting, we examined the effects of RSG on SESs, PESs, and bare metal stents endothelialization.


RESULTS
Animals receiving SESs, PESs, or bare metal stents and either RSG (3 mg/kg per day) or placebo were euthanized at 28 days, and arteries were evaluated by scanning electron microscopy. Fourteen-day organ culture and Western blotting of iliac arteries and tissue culture experiments were conducted. Endothelialization was significantly reduced by RSG in SESs but not in PESs or bare metal stents. Organ culture revealed reduced vascular endothelial growth factor in SESs receiving RSG compared to RSG animals receiving bare metal stent or PESs. Quantitative polymerase chain reaction in human aortic endothelial cells (HAECs) revealed that sirolimus (but not paclitaxel) inhibited RSG-induced vascular endothelial growth factor transcription. Western blotting demonstrated that inhibition of molecular signaling in SES+RSG-treated arteries was similar to findings in HAECs treated with RSG and small interfering RNA to PPARgamma, suggesting that sirolimus inhibits PPARgamma. Transfection of HAECs with mTOR (mammalian target of rapamycin) short hairpin RNA and with Akt2 small interfering RNA significantly inhibited RSG-mediated transcriptional upregulation of heme oxygenase-1, a PPARgamma target gene. Chromatin immunoprecipitation assay demonstrated sirolimus interferes with binding of PPARgamma to its response elements in heme oxygenase-1 promoter.


CONCLUSIONS
mTOR/Akt2 is required for optimal PPARgamma activation. Patients who receive SESs during concomitant RSG treatment may be at risk for delayed stent healing.
Finn
Aloke V
AV
Department of Medicine/Heart and Vascular Center, Emory University School of Medicine, Atlanta, GA, USA. avfinn@emory.edu
John
Michael
M
Nakazawa
Gaku
G
Polavarapu
Rohini
R
Karmali
Vinit
V
Xu
Xin
X
Cheng
Qi
Q
Davis
Talina
T
Raghunathan
Chitra
C
Acampado
Eduardo
E
Ezell
Tucker
T
Lajoie
Scott
S
Eppihimer
Michael
M
Kolodgie
Frank D
FD
Virmani
Renu
R
Gold
Herman Kalman
HK
D000818:Animals; D001011:Aorta / Q000378:metabolism; D002478:Cells, Cultured; D054855:Drug-Eluting Stents; D042783:Endothelial Cells / Q000378:metabolism; D006083:Graft Occlusion, Vascular; D051547:Heme Oxygenase-1 / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008954:Models, Biological; D047495:PPAR gamma / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology*; D011494:Protein Kinases / Q000235:genetics / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism*; D011817:Rabbits; D000077154:Rosiglitazone; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases; D045162:Thiazolidinediones / Q000494:pharmacology*; D050257:Tubulin Modulators / Q000494:pharmacology*
D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D050257:Tubulin Modulators; D000077154:Rosiglitazone; D051547:Heme Oxygenase-1; D011494:Protein Kinases; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D017239:Paclitaxel; D020123:Sirolimus